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Abstract
The effects of aspirin metabolites on L-oxidation were studied in skin fibroblasts from eight typical Reye’s syndrome (RS)
patients and controls. RS patients’ cells did not differ from controls in rates of palmitate oxidation or in the three component
activities of the mitochondrial trifunctional enzyme (MTE), indicating no inherited L-oxidation defect. Aspirin metabolites
salicylate, hydroxyhippurate and gentisate, but not aspirin, directly inhibited palmitate oxidation in control and RS cells. RS
cells were significantly more sensitive to inhibition than controls at 0.5 to 5 mM salicylate. Inhibition was concentration-
dependent and reversible. Inhibition did not occur in fibroblasts lacking activity of the long-chain 3-hydroxyacyl-CoA
dehydrogenase (LCHAD) activity of MTE. Salicylate was therefore inhibiting L-oxidation at this step. Hydroxyhippurate
and salicylate reversibly inhibited HAD activities in extracts of control and RS cells. Studies with pure short-chain HAD and
LCHAD (MTE) showed hydroxyhippurate and salicylate were competitive inhibitors of the former but mixed (not
competitive) inhibitors of the latter. Both compounds inhibited the combined, three-step, MTE reaction measured in the
physiological direction. We conclude that (1) salicylate and hydroxyhippurate decrease L-oxidation in intact cells by
reversible inhibition of LCHAD activity of the MTE, and (2) L-oxidation in RS cells is inherently more sensitive to inhibition
by low concentrations of salicylate than controls. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
Reye’s syndrome (RS) [1] is a biphasic illness of
childhood [2]. An acute viral prodrome is followed
by life-threatening encephalopathy with visceral fatty
in¢ltration and impairment of hepatic function. Liver
and brain of RS patients reveal mitochondrial abnor-
malities with swelling, decreased matrix density and
loss of cristae [3] and marked reduction of mitochon-
drial enzyme activities [4]. Mitochondrial function is
deranged disrupting ureagenesis and ketogenesis,
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Abbreviations: ASA, acetylsalicylic acid (aspirin); ECH, 2-
enoyl-CoA hydratase; FBS, foetal bovine serum; KAT, 3-ketoac-
yl-CoA thiolase; LCHAD or SCHAD, long-chain or short-chain
3-hydroxyacyl-CoA dehydrogenase; MTE, mitochondrial trifunc-
tional enzyme; PBS, phosphate-bu¡ered saline; RS, Reye’s syn-
drome
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causing hyperammonaemia, hypoglycaemia, with ele-
vated serum lactate, free fatty acids and dicarboxylic
acids [5^7]. Blockage of mitochondrial L-oxidation in
RS is indicated by ¢ndings of elevated acid soluble
acyl-CoA esters [8,9] and decreased free CoASH [9]
in livers from RS patients. Patients with inherited
defects in mitochondrial fatty acid L-oxidation
show Reye-like symptoms [10] but the similarity
with classical RS is closest in those with defective
mitochondrial L-oxidation of long-chain fatty acids
[11].
Ingestion of aspirin during the viral prodrome ap-
pears to trigger the cascade of events comprising RS
[12^14]. In support is the observation that RS inci-
dence dropped dramatically in the USA [15] and UK
following advice not to prescribe aspirin for children
[16]. Salicylate, the primary metabolite of aspirin,
inhibits L-oxidation of medium and long-chain fatty
acids in rodent liver mitochondria [17,18] (but not
peroxisomes) [17]. Salicylate decreases oxidation of
long-chain fatty acids by rat liver slices [19], rat hep-
atocytes [20] and in vivo in mice [18]. This e¡ect on
L-oxidation inhibits lactate-driven gluconeogenesis
[20]. Aspirin metabolites have structural similarities
to the acyl-portions of the substrate and product
(Fig. 1) of the 3-hydroxyacyl-CoA dehydrogenase
activity of the L-oxidation pathway. We propose
that aspirin metabolites could inhibit L-oxidation at
this step but that this inhibition would therefore not
occur in cells lacking this enzyme activity.
There have been no studies of the response of
L-oxidation in human tissue to aspirin metabolites
nor has the possibility been investigated that tissue
from RS patients might di¡er in response to these
compounds. This work was carried out to determine:
(1) the extent to which aspirin and its metabolites are
inhibitors of L-oxidation in intact cells, (2) their
mechanism of action, and (3) whether cells from sur-
vivors of RS di¡er in their responses to those from
controls.
2. Patients, materials and methods
2.1. Patients
Following informed consent, skin biopsies were
obtained for ¢broblast culture from eight typical pa-
tients who had recovered from RS. During the en-
cephalopathy each had a Reyescore (a system to score
clinical and pathological features; maximum 25) of
17 or greater. All but two had de¢nitely been given
aspirin (mean plasma salicylate concentration in
42 patients with RS seen in Northern Ireland from
1979 to 1986 was 1.0 mM). Skin ¢broblasts from
12 other children were investigated earlier for possi-
ble inherited metabolic disorders, three of whom had
enzymically proven long-chain 3-hydroxyacyl-CoA
dehydrogenase (LCHAD) de¢ciency. In these three,
the defect was group II [21] with normal K and L
subunits detectable by Western blotting (K. Carpen-
ter, B. Middleton, unpublished observations). The
remaining nine children were shown to be normal
and their ¢broblasts constituted the control group.
The protocol was approved by the Research Ethical
Committee of the Queen’s University, Belfast.
2.2. Materials
Enzymes, coenzymes, CoA derivatives, lipid stand-
ards, radioactive compounds and cell culture materi-
als were from Sigma-Aldrich Chemical Co., UK,
unless otherwise stated. 2-Hexadecenoyl-CoA was
synthesised enzymically at pH 7.5 from 1 mM
palmitoyl-CoA using 2.5 units acyl-CoA oxidase
(Boehringer Mannheim, UK). 3-ketopalmitoyl-CoA
was synthesised enzymically at pH 7.5 from 1 mM
2-hexadecynoyl-CoA using crotonase as described
by Thorpe [22]. These acyl-CoA compounds were
s 95% pure when analysed on HPLC.
Mitochondrial trifunctional enzyme (MTE) was
puri¢ed to homogeneity from human liver as de-
scribed [23]. Puri¢ed 3-hydroxyacyl-CoA dehydro-
genase from pig heart was purchased from Boehr-
inger Mannheim, UK.
2.3. Methods
Skin ¢broblasts were cultured in Dulbecco’s modi-
¢ed Eagle’s medium containing 10% (v/v) FBS and
antibiotics.
L-Oxidation was assayed at 37‡C in intact ¢bro-
blast monolayers in 24-well dishes. The process was
followed by release of 3H2O from 0.1 mM [9,10-
3H]palmitate (75.8 WCi/Wmol, 168 dpm/pmol) into
0.2 ml Krebs Ringer phosphate bu¡er, pH 6.9. The
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method was modi¢ed [24] from the original of Moon
and Rhead [25]. L-Oxidation was determined over 2 h
where rates were constant.
For the labelling of intracellular lipids, cells were
washed with PBS, and lipids extracted with hexane/
isopropanol (3:2, v/v) after incubation with
[3H]palmitate under identical conditions used for
the L-oxidation assay (above), but before protein de-
termination [26]. Extracted lipids were separated by
thin-layer chromatography on silica gel plates
(Merck) using hexane/diethyl ether/glacial acetic
acid at 90:10:1 (v/v). Lipid bands were detected by
rhodamine spray (0.02% v/v in acetone) and scraped
o¡ for scintillation counting. Recovery of standards
was similar (80^90%) for all lipid classes analysed.
For enzymic studies, cell monolayers in 25-cm2
£asks were washed with PBS, scraped into eppendorf
tubes and stored as pellets at 320‡C until required.
The enzyme activities were stable for months under
these conditions. Cell pellets were suspended in ice-
cold breakage bu¡er (50 mM sodium phosphate,
1 mM EDTA, 0.5% (v/v) Triton X-100, 1.25 mM
dithiothreitol, pH 8.2), sonicated for 3U10-s bursts
at 10-s intervals at 0‡C and spun brie£y at 14 000Ug
to clarify.
The activities of MTE (2-enoyl-CoA hydratase,
ECH; 3-hydroxyacyl-CoA dehydrogenase, HAD; 3-
ketoacyl-CoA thiolase, KAT) were determined at
30‡C by modi¢cations of methods described [23].
HAD was measured at 340 nm as the rate of oxida-
tion of 140 WM NADH in 100 mM potassium phos-
phate (pH 7.0) in the presence of 20 WM acetoacetyl-
or 3-ketopalmitoyl-CoA. This determines HAD ac-
tivity in the thermodynamically favourable, but non-
physiological, direction. KAT was measured at
303 nm as the rate of cleavage of 3-ketopalmitoyl-
CoA (10 WM) in 50 mM bis-tris-propane, 2 mM
MgCl2, 0.2% (v/v) Tween-20 (pH 9.0) plus 250 WM
CoASH. The OmM for 3-ketopalmitoyl-CoA was 16.0
at 303 nm. ECH was measured at 263 nm as the rate
of hydration of trans-2-hexadecenoyl-CoA (25 WM)
in 50 mM bis-tris-propane, pH 9.0. The vOmM for
trans-2-enoyl-CoA was 6.7 at 263 nm [22]. The com-
bined activity of the trifunctional enzyme was meas-
ured at 340 nm as the rate of reduction of NAD
(1.0 mM) in 100 mM potassium phosphate, 0.2%
(v/v) Tween-20 (pH 7.0) in the presence of 25 WM
trans-2-hexadecenoyl-CoA and 250 WM CoASH.
Under these conditions the 2-enoyl-CoA is quantita-
tively converted to acyl-CoA+acetyl-CoA with no
accumulation of 3-ketoacyl-CoA intermediate and
with stoichiometric reduction of NAD [27]. For ki-
netic studies, the acyl-CoA concentrations of the
above assays were varied and rates measured þ inhi-
bitor.
Statistical analysis was with Excel v5.0 (Microsoft,
USA) using unpaired, paired t-test or analysis of
variance as appropriate. Kinetic analyses and calcu-
lation of Ki values þ standard errors used EnzymeKi-
netics v1.5 (Trinity Software, Plymouth, NH, USA).
3. Results
Rates of palmitate L-oxidation were similar in ¢-
broblasts from RS patients and controls (Table 1).
Control rates were similar to those previously re-
ported [28]. Because of structural similarities between
ASA metabolites and 3-hydroxyacyl-CoA dehydro-
genase substrates (Fig. 1), we compared the data
from RS and control cells with those from ¢broblasts
Fig. 1. Structural similarities between the aspirin metabolites
salicylate, gentisate and hydroxyhippurate, and the L-oxidation
intermediates 3-hydroxyacyl-CoA and 3-ketoacyl-CoA.
BBADIS 61832 11-5-99
J.F.T. Glasgow et al. / Biochimica et Biophysica Acta 1454 (1999) 115^125 117
de¢cient in long-chain 3-hydroxyacyl-CoA dehydro-
genase (LCHAD). LCHAD-de¢cient cells showed a
66% decrease in palmitate oxidation rate which cor-
related with their reduced LCHAD activity (Table 1
and [28]). Neither LCHAD nor the other two com-
ponent activities of the mitochondrial trifunctional
L-oxidation enzyme (MTE) in extracts of RS patients
cells were signi¢cantly di¡erent from control values
(Table 1). Thus no overt di¡erence existed in the
L-oxidation capacities of RS and control ¢broblasts.
We examined the e¡ect of added aspirin metabo-
lites on L-oxidation by RS and control cells. Aspirin
did not inhibit at up to 15 mM (data not shown), but
salicylate, hydroxyhippurate and gentisate all caused
signi¢cant, concentration-related inhibition of palmi-
tate oxidation in control and RS cells (Figs. 2 and 3).
This inhibition did not increase with time. L-Oxida-
tion in control and RS ¢broblasts was similarly af-
fected by increasing concentrations of hydroxyhippu-
rate and gentisate, inhibition reaching 30% by 6 mM
and 50% by 12 mM. However, salicylate a¡ected
palmitate oxidation di¡erentially in ¢broblasts from
controls and RS patients. RS patients cells were
more inhibited at low concentrations of salicylate
(Fig. 2). Inhibition began at 0.5 mM and was 18%
(P6 0.05, paired t-test) at 1 mM. But in control cells,
0.5 to 1 mM salicylate signi¢cantly enhanced (Fig. 2)
the rate of L-oxidation. Salicylate at 5 mM inhibited
control rates by 11% (P6 0.01, paired t-test) while
RS cell rates were inhibited by 29% (P6 0.01, paired
t-test). At higher concentrations of salicylate the ef-
fect on rates of palmitate oxidation in RS and con-
trol cells converged, causing 45% and 43% inhibition,
respectively, at 15 mM.
Since salicylate can be toxic to hepatocytes in pri-
mary culture [29], the consequences of 48 h exposure
of ¢broblasts to inhibitory concentrations of aspirin
metabolites were studied. After 48 h pre-incubation,
cells were assayed for palmitate oxidation in the ab-
sence of inhibitor. Pre-incubation with salicylate, hy-
droxyhippurate or gentisate had no e¡ect on the rate
of palmitate oxidation when expressed per well or
per mg cell protein (Table 2). None of the aspirin
metabolites caused any signi¢cant decrease in yield
of cell protein or change in appearance of the
cells. Thus the ASA metabolites used here exerted
Table 1
Palmitate L-oxidation rates and L-oxidation trifunctional enzyme activities (2-enoyl-CoA hydratase, ECH; 3-hydroxyacyl-CoA dehy-
drogenase, HAD; 3-ketoacyl-CoA thiolase, KAT) of skin ¢broblasts from controls, Reye’s syndrome patients and patients with
LCHAD de¢ciency, group II
Cell origin n Palmitate oxidation
(pmol/min/mg)
HAD
(nmol/min/mg)
KAT
(nmol/min/mg)
ECH
(nmol/min/mg)
Controls 9 71.5 þ 12.0 101.5 þ 15.3 143.8 þ 30.0 44.6 þ 6.6
Reye’s syndrome 8 78.0 þ 8.6 146.8 þ 17.0 140.5 þ 19.0 56.2 þ 4.0
LCHAD de¢ciency 3 24.5 þ 8.5* 27.5 þ 6.9* 99.0 þ 36.1 33.8 þ 2.3
See Section 2 for details of cell growth and assays. Values are means þ S.E.M. n, number of individuals. Activities of HAD, KAT and
ECH were determined with acyl-CoAs of C16 chain length. *P6 0.01 with respect to controls (unpaired t-test).
Fig. 2. Salicylate inhibits palmitate L-oxidation di¡erentially in
¢broblasts from controls (n = 6) and RS patients (n = 6) (E and
F, respectively). Rates are percent of the zero salicylate value
within each independent experiment and are presented as means
þ S.E.M. These zero salicylate rates were 68 þ 12 and 72 þ 16
pmol/min per mg þ S.E.M., respectively, for controls or RS
cells. Where the error bars are not visible they fall within the
symbol. *P6 0.01 (paired t-test) for control rates at 1 mM sali-
cylate (74 þ 12 pmol/min per mg þ S.E.M.) compared to rates at
zero salicylate. P6 0.01 (ANOVA) for RS compared to con-
trols at the same concentration of salicylate.
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a reversible e¡ect on skin ¢broblast palmitate oxida-
tion.
We used the cellular L-oxidation assay system to
investigate the possible site of action of salicylate in
intact skin ¢broblasts by measuring the steady state
levels of [3H]palmitate-derived radioactivity in vari-
ous cell lipids. 3H-Labelling of palmitate-derived lip-
ids such as phospholipids and cholesteryl esters re-
quires initial synthesis of [3H]palmitoyl-CoA so that
inhibition of this step by salicylate [18] should reduce
the amount of [3H]phospholipid and [3H]cholesteryl
esters. Only slight inhibition of labelling of phospho-
lipids and cholesteryl esters was detected over the
range 0^15 mM salicylate (Table 3). Thus salicylate
caused little biologically signi¢cant inhibition of pal-
mitate conversion to palmitoyl-CoA in human skin
¢broblasts. In contrast, labelling of cholesterol was
progressively inhibited up to 60% by increasing con-
Fig. 3. Hydroxyhippurate (a) and gentisate (b) inhibit L-oxida-
tion of palmitate in cells from controls (E) and RS patients
(R). Rates are percent of the zero inhibitor value within each
independent experiment and are presented as means. The zero
inhibitor mean rates for control and RS cells, respectively
(pmol/min per mg þ S.E.M., n individuals) were (a) 55 þ 3
(n = 6), 72 þ 9 (n = 6); and (b) 89 þ 15 (n = 3), 116 (n = 2). There
were no signi¢cant di¡erences between controls and RS pa-
tients’ cells in response to the di¡erent inhibitors ; for clarity,
error bars are not shown.
Table 2
E¡ect of preincubation with inhibitory concentrations of aspirin metabolites on palmitate oxidation rates in skin ¢broblasts from con-
trols and Reye’s syndrome patients
Inhibitor in preincubation Fibroblasts from:
Controls (4) RS (4)
Expt. I None 47.6 þ 2.5 66.8 þ 2.1
Salicylate (10 mM) 51.7 þ 1.0 74.0 þ 4.1
Hydroxyhippurate (6 mM) 56.6 þ 6.4 60.5 þ 1.8
Expt. II None 62.0 þ 2.7 50.6 þ 3.9
Gentisate (6 mM) 56.2 þ 1.9 52.3 þ 2.8
Cells were preincubated for 48 h at 37‡C with the stated concentrations of aspirin metabolites. These were added to the growth me-
dium immediately after plating out into multiwell dishes. Growth medium containing the same concentration of metabolite was re-
newed after 24 h, and 24 h later the cells were washed with PBS for 2 h at 37‡C before being assayed for palmitate oxidation capacity
in the absence of added inhibitors (as described in Section 2). Rates are expressed as pmol/min per mg and are means þ S.D. for the
number of individuals in parentheses.
Fig. 4. Salicylate does not inhibit L-oxidation of palmitate in
cells from three patients with LCHAD de¢ciency type II (a).
Rates are percent of the zero salicylate value within each inde-
pendent experiment and are presented as means þ S.E.M. The
zero salicylate mean rate (pmol/min per mg þ S.E.M.) was
18 þ 4 (n = 3). Comparison is made with salicylate inhibition
of the same process in cells from six controls (F, data from
Fig. 2).
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centrations of salicylate (Table 3). Formation of
[3H]cholesterol requires mitochondrial L-oxidation
of [3H]palmitoyl-CoA to [3H]acetyl-CoA and subse-
quent biosynthesis from this precursor [30]. These
data from intact cells are consistent with salicylate
inhibition of palmitate L-oxidation but not primarily
at the level of palmitoyl-CoA formation [18].
Salicylate had no signi¢cant inhibitory e¡ect on
palmitate oxidation by skin ¢broblasts de¢cient in
LCHAD activity (Fig. 4). These cells also showed
no inhibitory response to hydroxyhippurate, rates
averaging 104% of zero inhibitor value over the
range 2^8 mM. Low concentrations of salicylate
caused a 20% increase in L-oxidation rate (Fig. 4)
(as in controls) but there was no inhibition at any
concentration of salicylate up to 15 mM. At 15 mM
salicylate, palmitate oxidation rates were still 110%
of zero salicylate values. This response contrasted
with that of controls (Figs. 2 and 4) or RS cells
(Fig. 2) and indicated that the inhibitory e¡ects of
salicylate and hydroxyhippurate on L-oxidation oc-
cur at the site of LCHAD activity.
In extracts from controls and RS ¢broblasts, both
salicylate and hydroxyhippurate inhibited HAD ac-
tivity measured with C16-(3-ketopalmitoyl-CoA) and
C4-(acetoacetyl-CoA) substrates. (The optical prop-
erties of gentisate prevented its use in these assays.)
Inhibition was reversible; HAD activity was unaf-
fected after culturing cells with 10 mM salicylate
for 48^72 h. The inhibition was not time-dependent
Table 3
The e¡ect of salicylate on the labelling of cellular lipids during incubation of skin ¢broblasts with [3H]palmitate
[Salicylate] (mM) 3H-labelling of cellular lipids
Phospholipid Cholesteryl ester Cholesterol
0 163 911 þ 27 400 2907 þ 119 7555 þ 2046
5 143 763 þ 40 656 3077 þ 1539 4569 þ 1885
15 127 619 þ 25 903 2594 þ 1346 3042 þ 1258*
After 2 h with [3H]palmitate, cell lipids were extracted, separated by thin-layer chromatography and their radioactivity determined per
mg cell protein as described in Section 2. Results are from three independent experiments with cells from two individuals. Since the
speci¢c activity of [3H]acetyl-CoA was not determined, data are expressed as mean dpm/mg protein þ S.D. *P6 0.05 with respect to
zero salicylate controls.
Fig. 5. Salicylate (a) and hydroxyhippurate (b) inhibit HAD ac-
tivity in RS cell extracts. Extracts were prepared in replicate
from six di¡erent RS cell lines. HAD activity was determined
from initial rates of reduction of 3-ketopalmitoyl-CoA as de-
scribed in Section 2. Data are presented as mean þ S.E.M. Zero
inhibitor activity was (a) 139 þ 21 nmol/min per mg and (b)
123 þ 18 nmol/min per mg.
Fig. 6. Kinetics of the reversible inhibition by salicylate and hy-
droxyhippurate of puri¢ed hydroxyacyl-CoA dehydrogenases (a)
SCHAD, 0.04 Wg/ml, and (b) LCHAD (MTE), 0.26 Wg/ml.
Data are means of replicate initial rates measured in the pres-
ence of the stated concentrations of short-chain (a) or long-
chain (b) 3-ketoacyl-CoA substrate in the presence of: (a) 8,
no inhibitor; F, 15 mM salicylate; R, 6 mM hydroxyhippu-
rate; and (b) 8, no inhibitor; F, 15 mM salicylate; R, 12 mM
hydroxyhippurate.
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but was concentration-related. In extracts of ¢bro-
blasts from RS patients inhibition of HAD activity
was half maximal at 7.5 mM salicylate and 2.5 mM
hydroxyhippurate (Fig. 5). Similar inhibition of
HAD activity was seen in extracts of control cells
(data not shown).
The majority (s 90%) of HAD activity in cell ex-
tracts is due to two mitochondrial enzymes [23,31].
The ‘short-chain’ HAD (SCHAD) is most active with
acetoacetyl-CoA but contributes approximately 25%
to ¢broblast extract activity with 3-ketopalmitoyl-
CoA. The LCHAD of the MTE is most active with
3-ketopalmitoyl-CoA and is inactive with acetoace-
tyl-CoA [23,31]. Salicylate and hydroxyhippurate
were competitive inhibitors of SCHAD with respect
to acetoacetyl-CoA (Fig. 6a) with Ki values ( þ S.E.)
of 16.1 þ 1.7 mM and 2.4 þ 0.2 mM, respectively. In
contrast, both salicylate and hydroxyhippurate
caused mixed (not competitive) inhibition of
LCHAD with respect to 3-ketopalmitoyl-CoA (Fig.
6b). Mixed inhibition is caused by the inhibitor bind-
ing to both free and substrated enzyme, giving a Ki
for each interaction (Table 4). In the LCHAD reac-
tion the inhibitors interacted more strongly with free
enzyme (Table 4) giving Ki values ( þ S.E.) of
18.3 þ 2.6 mM for salicylate and 4.1 þ 0.4 mM for
hydroxyhippurate.
In vivo, MTE catalyses three consecutive reactions
of L-oxidation (Eqs. 1^3), below) in which the HAD
reaction proceeds in the reverse direction to that
measured above. This combined MTE reaction can
be followed in vitro in the presence of long-chain
2-enoyl-CoA, NAD and CoASH.
RCH  CHCOSCoAH2O!
RCH2OHCH2COSCoA 1
RCH2OHCH2COSCoANAD !
RCOCH2COSCoANADHH 2
RCOCH2COSCoA CoASH! RCOSCoA
CH3COSCoA 3
Table 4
Dissociation constants (Ki) for interaction of salicylate (SA) or hydroxyhippurate (HHA) with pure MTE
Enzyme reaction Inhibitors Dissociation constants (Ki, mM) for enzyme (E) or
substrated enzyme (ES) interaction with inhibitors
(I) as speci¢ed below:
EI = E+I ESI = ES+I
LCHAD SA 18.3 þ 2.6 48.0 þ 1.5
HHA 4.1 þ 0.4 21.0 þ 0.7
MTE SA 36.0 þ 1.3 4.6 þ 0.1
HHA 19.6 þ 2.5 2.2 þ 0.1
Ki values þ standard errors (six determinations) with acyl-CoA as variable substrate calculated as in Section 2. LCHAD denotes HAD
reaction measured as in Fig. 6b in the non-physiological direction; MTE denotes combined MTE reactions measured as in Fig. 7 in
the physiological direction.
Fig. 7. Kinetics of the reversible inhibition by salicylate and hy-
droxyhippurate of the three-step reaction catalysed by MTE,
4.6 Wg/ml, in the physiological direction (see Section 2). Data
are means of replicate initial rates measured in the presence of
the stated concentrations of 2-hexadecenoyl-CoA substrate
with: F, 10 mM salicylate; R, 12 mM hydroxyhippurate; 8,
no inhibitor.
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Both salicylate and hydroxyhippurate inhibited the
combined MTE reaction (Fig. 7) by mixed mecha-
nisms with respect to 2-hexadecenoyl-CoA. The in-
hibitors interacted most strongly with substrated en-
zyme (Table 4) giving Ki values ( þ S.E.) of 4.6 þ 0.1
mM for salicylate and 2.2 þ 0.1 mM for hydroxyhip-
purate. This inhibition decreased the Vmax for the
combined MTE reaction in the physiological direc-
tion (Fig. 7).
4. Discussion
This is the ¢rst study to examine e¡ects of ASA
metabolites on L-oxidation in intact cells from RS
patients and controls. We found that inhibition of
L-oxidation of [9,10-3H]palmitate by ASA metabo-
lites was a general phenomenon, seen in skin ¢bro-
blasts from 17 individuals. In control cells hydroxy-
hippurate and gentisate were more inhibitory than
salicylate at concentrations below 5 mM but cells
from RS patients were equally sensitive to all ASA
metabolites (Figs. 2 and 3). Thus salicylate, at 5 mM
or below, was a more e¡ective inhibitor of L-oxida-
tion in RS cells than in controls (Fig. 2). Due to the
rapid metabolism of ASA to salicylate (t1=2 = 15 min
in plasma [32]), these concentrations of salicylate can
be attained through normal use. Indeed optimal anti-
in£ammatory e¡ects of ASA are found when plasma
salicylate is greater than 1 mM [32]. Patients acutely
ill with RS had sixfold higher mean serum salicylate
concentrations (0.9 mM) than patients (controls)
with viral illnesses similar to the prodrome of RS
[33]. RS patients in the acute phase showed twofold
higher serum concentrations of hydroxyhippurate
than salicylate [34]. These data indicate that in the
acute phase of RS the concentration of ASA metab-
olites could increase to millimolar values capable of
causing signi¢cant inhibition of L-oxidation.
In this study L-oxidation was measured in intact
cells by release of 3H2O from [9,10-3H]palmitate
[24,25]. Manning et al. [24] described the theory be-
hind the use of this method. L-oxidation releases 25%
of the 3H from [9,10-3H]palmitate as [3H]acetyl-CoA
with the remaining 75% as 3H2O. Manning et al.
assumed that all the 3H from [3H]acetyl-CoA would
be rapidly released as 3H2O by further metabolism.
Our results (Table 3) show that some of this
[3H]acetyl-CoA is incorporated into cholesterol.
This is a very small proportion (6 1%) of the total
3H removed as 3H2O during the assay, con¢rming
the assumptions of Manning et al. We used the for-
mation of [3H]acetyl-CoA to show that salicylate’s
e¡ect on palmitate oxidation was not caused by a
block in palmitate uptake or palmitate activation
but was due to inhibition of the mitochondrial
L-oxidation pathway (Table 3).
Further evidence for the site of action of salicylate
and hydroxyhippurate on mitochondrial L-oxidation
was obtained by use of ¢broblasts from individuals
with LCHAD de¢ciency (group II). The complete
lack of inhibition of L-oxidation by salicylate or hy-
droxyhippurate in ¢broblasts with this de¢ciency,
compared to controls (Fig. 4) or RS cells, indicated
that the LCHAD activity of MTE is the target for
their inhibitory e¡ects on L-oxidation. LCHAD de-
¢ciency group II is due to total inactivity of the
LCHAD component of MTE (without change in
gross structure or loss of the other two enzymatic
functions) [35]. This absence results in only 66% re-
duction of L-oxidation rates in whole cell assays (Ta-
ble 1 and [28]) and 65^75% loss of LCHAD activity
in cell extracts (Table 1 and [28,36]) but causes severe
e¡ects in patients [37]. Although the remaining activ-
ity is contributed by the mitochondrial SCHAD [36],
it does not compensate for loss of LCHAD in these
patients. Likewise, incomplete inhibition of L-oxida-
tion by ASA metabolites in whole-cell assays (Figs. 2
and 3) could be associated with equally severe clin-
ical consequences.
Using pure enzymes, we showed that salicylate and
HHA inhibited both SCHAD and LCHAD (MTE),
the two mitochondrial enzymes responsible for 3-hy-
droxyacyl-CoA dehydrogenase activity in cell ex-
tracts. However, the mechanism of the inhibition dif-
fered, being competitive with respect to 3-ketoacyl-
CoA for SCHAD, while it was of mixed type (not
competitive) for LCHAD (MTE). When MTE activ-
ity was measured in the physiological direction as
three consecutive L-oxidation reactions, the mecha-
nism of inhibition by salicylate and hydroxyhippu-
rate was still of mixed type. Intermediate channelling
occurs within the 3 component activities of the MTE
[38] and this complicates the interpretation of the
kinetic mechanism of inhibition observed here. It
cannot be assumed that each of the catalytic domains
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are independent; inhibitor binding could in£uence
more than one domain. Since the aspirin metabolites
reduce the Vmax of the MTE reaction, their e¡ect
cannot be overcome by further accumulation of
acyl-CoA substrates thus causing more profound in-
hibition of MTE than their competitive inhibition of
the monofunctional SCHAD. This could explain why
the SCHAD activity did not appear to be inhibited
by ASA metabolites in intact cells.
MTE could also be the target for inhibition of
mitochondrial L-oxidation by the anti-epileptic agent
valproate, which also causes RS-like symptoms after
viral infection [39]. The metabolite 2,4-dien-valproate
binds to the K-subunit of MTE [40] which contains
the LCHAD domain of MTE but it was not deter-
mined whether 2,4-dien-valproate inhibited LCHAD
activity.
Our studies show that ¢broblasts from RS patients
were signi¢cantly more sensitive than control cells to
inhibition of L-oxidation by salicylate (Fig. 2). The
di¡erence lay in the stimulation of palmitate oxida-
tion rate in controls by 0.5^1 mM salicylate. This
e¡ect reached statistical signi¢cance (P6 0.05, paired
t-test) at 1 mM salicylate but higher concentrations
of salicylate caused increasing inhibition. Similar
stimulatory then inhibitory e¡ects of salicylate on
L-oxidation by rat liver slices have been reported
[19]. We showed that this stimulatory (9^21%) e¡ect
of salicylate was present, over a wide range of con-
centrations, even in ¢broblasts de¢cient in LCHAD
activity (Fig. 4) in which basal L-oxidation rates were
34% of controls and where salicylate never inhibited.
Thus stimulatory and inhibitory e¡ects of salicylate
were independent. Only the inhibition of L-oxidation
required presence of LCHAD activity.
Mitochondrial fatty acid oxidation is controlled by
the redox state [41,42]. Uncoupling increases the pro-
portion of oxidised to reduced redox carriers in mi-
tochondria and stimulates L-oxidation rates. Salicy-
late causes uncoupling of mitochondrial oxidation
from phosphorylation but neither gentisate nor hy-
droxyhippurate are uncouplers [43,44]. Thus the
stimulatory e¡ects, seen at low concentrations of sa-
licylate but not hydroxyhippurate or gentisate, on L-
oxidation rates in control cells could be due to spe-
ci¢c uncoupling by salicylate via an uncoupling pro-
tein. It is possible that in RS cells, salicylate does not
uncouple oxidative phosphorylation because the spe-
ci¢c target protein is absent. Lack of this gene prod-
uct might explain the di¡erence in L-oxidation re-
sponse to low concentrations of salicylate between
controls and LCHAD de¢cient cells on the one
hand, and RS cells on the other. This di¡erence
needs further investigation.
In conclusion, we have identi¢ed the target for
inhibitory e¡ects of aspirin metabolites on L-oxida-
tion in intact ¢broblasts from controls and RS pa-
tients. We have demonstrated that L-oxidation by RS
cells is peculiarly sensitive to inhibition by concen-
trations of salicylate which are in the therapeutic
range. This sensitivity, if widely expressed in body
tissues, could explain the reaction of certain individ-
uals to aspirin thus contributing to Reye’s syndrome.
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